![]() |
Lina BadimonBarcelona, Spain PATHOGENESIS OF ATHEROSCLEROSIS Microvesicles and endothelial activation |
![]() |
Colin BaigentOxford, UK PREVENTION AND TREATMENT OF CVD Chronic kidney disease patients |
![]() |
Marianne BennDenmark ADVANCED CLINICAL SEMINARS Overweight - lifestyle and drugs |
![]() |
Mariette BookLeiden, The Netherlands |
![]() |
Mariëtte BoonLeiden, The Netherlands |
![]() |
Rosalind ColemanNorth Carolina, USA |
![]() |
Rosalind ColemenChapel Hill, USA ADVANCED CLINICAL SEMINARS Natural history of NAFLD |
![]() |
Victoria DelgadoLeiden, The Netherlands JOINT SYMPOSIUM How to approach a patient with dyslipidemia without apparent CAD (case by Baris Gencer 5 min) What the guideline says |
![]() |
Sven FranqueAntwerp, Belgium ADVANCED CLINICAL SEMINARS Emerging clinical trials to combat NAFLD |
![]() |
Elina IkonenHelsinki, Finland METABOLISM OF LIPIDS AND LIPOPROTEINS Intracellular cholesterol trafficking |
![]() |
Folkert KuipersGroningen, The Netherlands METABOLISM OF LIPIDS AND LIPOPROTEINS The role of FXR in reverse cholesterol transport |
![]() |
Ulrich LaufsLeipzig, Germany ADVANCED CLINICAL SEMINARS Management of stable coronary heart disease patients EDUCATIONAL CME ACCREDITED PROGRAMME When do we need add on therapies to statin? The Changing Face of HoFH How did the ESC/EAS guidelines change my practice? The Changing Face of HoFH On the horizon: Novel options for the combination of LDL-C lowering therapies |
![]() |
François MachGeneva, Switzerland JOINT SYMPOSIUM How to approach a patient with dyslipidemia with CAD (case by Anna Lebedeva 5 min) What the guideline says EDUCATIONAL CME ACCREDITED PROGRAMME Are the new EAS/ESC lipids goals reachable in clinical practice? The Changing Face of HoFH Introduction. Targeting PCSK9: from bench to real world The Changing Face of HoFH LDL-C reduction: earlier, lower, better! The Changing Face of HoFH LIVE Panel discussion: with a focus on very-high risk patients The Changing Face of HoFH Conclusions and take- home messages The Changing Face of HoFH New LDL-C goals: Practical implications for the management of patients with residual risk |
![]() |
David NanchenLausanne, Switzerland ADVANCED CLINICAL SEMINARS Limited specificity: scores overestimate risk |
![]() |
Børge NordestgaardCopenhagen, Denmark ADVANCED CLINICAL SEMINARS Limited sensitivity: scores underestimate risk |
![]() |
Yael NossentVienna, Austria PATHOGENESIS OF ATHEROSCLEROSIS The multifactorial nature of microRNAs in vascular remodelling |
![]() |
Katariina ÖörniHelsinki, Finland PATHOGENESIS OF ATHEROSCLEROSIS LDL aggregation |
![]() |
Elena OstoCzech Republic METABOLISM OF LIPIDS AND LIPOPROTEINS G-protein coupled bile acid receptors |
![]() |
Eva PrescottCopenhagen, Denmark ADVANCED CLINICAL SEMINARS Impact of smoking and psycosocial health |
![]() |
Paolo RaggiAlberta, Canada PREVENTION AND TREATMENT OF CVD Refinement of risk prediction by imaging |
![]() |
Pelin SahlénSweden PATHOGENESIS OF ATHEROSCLEROSIS High-resolution regulatory maps connect vascular risk variants to disease-related pathways |
![]() |
Kristina SchoonjansLausanne, Switzerland |
![]() |
Bill SessaUSA |
![]() |
Oliver SoehnleinMunich, Germany PATHOGENESIS OF ATHEROSCLEROSIS Vulnerable plaque: Current concepts in pathophysiology and imaging |
![]() |
Qi SunUSA |
![]() |
Bart van de SluisGroningen, The Netherlands METABOLISM OF LIPIDS AND LIPOPROTEINS Role of the retromer COMMD/WASH complex |
![]() |
Cherian VargheseGeneva, Switzerland |
![]() |
Tobias WaltherUSA METABOLISM OF LIPIDS AND LIPOPROTEINS Impact of lipid droplets - implications for human disease |
![]() |
Marit WesterterpGroningen, The Netherlands PATHOGENESIS OF ATHEROSCLEROSIS Inflammasome, neutrophil extracellular traps and cholesterol |
![]() |
Stephan WindeckerSwitzerland |
![]() |
Christian WolfrumZürich, Switzerland METABOLISM OF LIPIDS AND LIPOPROTEINS Whitening of brown adipose tissue - role of the mevalonate pathwa |
![]() |
Jose Luis ZamoranoSpain PREVENTION AND TREATMENT OF CVD Acute coronary syndrome patients |
![]() |
Tanja ZellerHamburg, Germany |
![]() |
Alma ZerneckeWürzburg, Germany PATHOGENESIS OF ATHEROSCLEROSIS Transcriptomic landscape and heterogeneity of macrophages in atherosclerosis. |
![]() |
Francesca ZimettiParma, Italy METABOLISM OF LIPIDS AND LIPOPROTEINS Lipoprotein transport in the brain |